StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly & Co. (LLY), Aduro Biotech, Inc. (ADRO) Report Research Collaboration & License Agreement to Develop Novel Immunotherapies
December 18, 2018 4:18 PM
Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Management Comments
Next Articles
Eli Lilly & Co. (LLY) Raises Quarterly Dividend 14.7% to $0.645; 2.4% Yield
December 19, 2018 6:26 AM
Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies
December 18, 2018 4:15 PM
Lilly (LLY) announces publication of analyses showing benefit of addition of Verzenio in multiple subgroups of patients with advanced breast cancer
December 18, 2018 6:46 AM
Lilly (LLY) Says Taltz met primary and all major secondary endpoints in Phase 3b/4 SPIRIT-H2H study
December 17, 2018 6:46 AM
Lilly (LLY) to Buy Pre-Clinical Pain Program from Hydra Biosciences
December 14, 2018 3:30 PM
Merck bolsters animal health unit with $2.4 billion Antelliq purchase
December 14, 2018 7:05 AM
Eli Lilly & Co. (LLY) Announces Expanded Collaboration with Evidation Health to Analyze Data from Smartphones & Connected Sensors
December 14, 2018 6:46 AM
